DJIA 17,826.30 -279.47 -1.54%
NASDAQ 4,931.82 -75.98 -1.52%
S&P 500 2,081.18 -23.81 -1.13%
market minute promo

Novartis (NYSE: NVS)



company name or ticker
Company Photos
(Click to zoom)

Is This The Biggest Threat to Isis Pharmaceuticals Stock?

Isis Pharmaceuticals has garnered a massive premium based on the potential of its antisense drug pipeline. With numerous companies entering the rare disease field, though, Isis' drugs might face stiff competition. So are investors being overly optimistic?

Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog

11 Promising New Drugs Expected to Make Billions in Sales

This Market Could Grow 6250% in 10 Years

With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.

CELG Stock - Here's Why Celgene Is Worth Snapping Up

Dividend Stocks: 2 to Avoid, 1 to Buy

Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.

Novartis International AG: New Novartis data shows Cosentyx is significantly superior to Stelara and

Novartis International AG: New Novartis data shows Cosentyx is significantly superior to Stelara and clears skin (PASI 90

Novartis (NVS) Leading In Pre-Market Activity

How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios

How The Rushed Biosimilar Law Is Yielding Go-Slow Launches

See More Articles...